Technical problem

No agreed dose for a VR therapy

Session length, weekly frequency and total course vary widely between VR trials, and the best-performing settings differ by outcome and population. Without a standard dose, studies are hard to compare and a product's labelled regimen is hard to justify.

StageClinical validation

Addressed by

Nothing in the catalog addresses this yet

This is a real gap rather than a missing page. If you know work that addresses it, suggest a record.

Provenance

Where this problem statement comes from

Frontiers in Neurology — VR balance and gait training in Parkinson's disease: dose-response meta-analysisMeta-analysis of 32 trials found optimal session length and frequency differed between balance and walking outcomes and by region. The problem statement is AVRMD's framing; the cited work documents the difficulty.